Literature DB >> 21869466

The evolutionary landscape of antifolate resistance in Plasmodium falciparum.

Marna S Costanzo1, Daniel L Hartl.   

Abstract

Resistance to antifolates in Plasmodium falciparum is well described and has been observed in clinical settings for decades. At the molecular level, point mutations in the dhfr gene that lead to resistance have been identified, and the crystal structure of the wildtype and mutant dihydrofolate reductase enzymes have been solved in complex with native substrate and drugs. However, we are only beginning to understand the complexities of the evolutionary pressures that lead to the evolution of drug resistance in this system. Microbial systems that allow heterologous expression of malarial proteins provide a tractable way to investigate patterns of evolution that can inform our eventual understanding of the more complex factors that influence the evolution of drug resistance in clinical settings. In this paper we will review work in Escherichia coli and Saccharomyces cerevisiae expression systems that explore the fitness landscape of mutations implicated in drug resistance and show that (i) a limited number of evolutionary pathways to resistance are followed with high probability; (ii) fitness costs associated with the maintenance of high levels of resistance are modest; and (iii) different antifolates may exert opposing selective forces.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21869466      PMCID: PMC3212943          DOI: 10.1007/s12041-011-0072-z

Source DB:  PubMed          Journal:  J Genet        ISSN: 0022-1333            Impact factor:   1.166


  26 in total

1.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.

Authors:  James G Kublin; Fraction K Dzinjalamala; Deborah D Kamwendo; Elissa M Malkin; Joseph F Cortese; Lisa M Martino; Rabia A G Mukadam; Stephen J Rogerson; Andres G Lescano; Malcolm E Molyneux; Peter A Winstanley; Phillips Chimpeni; Terrie E Taylor; Christopher V Plowe
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

2.  Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan.

Authors:  Abdel-Muhsin A Abdel-Muhsin; Margaret J Mackinnon; Eltayeb Ali; El-Khansaa A Nassir; Suad Suleiman; Salah Ahmed; David Walliker; Hamza A Babiker
Journal:  J Infect Dis       Date:  2004-03-16       Impact factor: 5.226

3.  Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli.

Authors:  Sudsanguan Chusacultanachai; Pornpan Thiensathit; Bongkoch Tarnchompoo; Worachart Sirawaraporn; Yongyuth Yuthavong
Journal:  Mol Biochem Parasitol       Date:  2002-03       Impact factor: 1.759

4.  Altered dihydrofolate reductase associated with a pyrimethamine-resistant Plasmodium berghei berghei produced in a single step.

Authors:  S M Diggens; W E Gutteridge; P I Trigg
Journal:  Nature       Date:  1970-11-07       Impact factor: 49.962

5.  Reciprocal cross resistance between cycloguanil hydrochloride and pyrimethamine in Plasmodium berghei infections in mice.

Authors:  P E Thompson; A Bayles
Journal:  J Parasitol       Date:  1968-06       Impact factor: 1.276

6.  Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.

Authors:  D S Peterson; D Walliker; T E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum.

Authors:  A F Cowman; M J Morry; B A Biggs; G A Cross; S J Foote
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Heterologous expression of active thymidylate synthase-dihydrofolate reductase from Plasmodium falciparum.

Authors:  W Sirawaraporn; R Sirawaraporn; A F Cowman; Y Yuthavong; D V Santi
Journal:  Biochemistry       Date:  1990-12-04       Impact factor: 3.162

9.  Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance.

Authors:  G Rastelli; W Sirawaraporn; P Sompornpisut; T Vilaivan; S Kamchonwongpaisan; R Quarrell; G Lowe; Y Thebtaranonth; Y Yuthavong
Journal:  Bioorg Med Chem       Date:  2000-05       Impact factor: 3.641

10.  Fitness trade-offs in the evolution of dihydrofolate reductase and drug resistance in Plasmodium falciparum.

Authors:  Marna S Costanzo; Kyle M Brown; Daniel L Hartl
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

View more
  17 in total

1.  Epistasis as the primary factor in molecular evolution.

Authors:  Michael S Breen; Carsten Kemena; Peter K Vlasov; Cedric Notredame; Fyodor A Kondrashov
Journal:  Nature       Date:  2012-10-14       Impact factor: 49.962

2.  A Two-Enzyme Adaptive Unit within Bacterial Folate Metabolism.

Authors:  Andrew F Schober; Andrew D Mathis; Christine Ingle; Junyoung O Park; Li Chen; Joshua D Rabinowitz; Ivan Junier; Olivier Rivoire; Kimberly A Reynolds
Journal:  Cell Rep       Date:  2019-06-11       Impact factor: 9.423

3.  Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance.

Authors:  Amanda K Lukens; Leila Saxby Ross; Richard Heidebrecht; Francisco Javier Gamo; Maria J Lafuente-Monasterio; Michael L Booker; Daniel L Hartl; Roger C Wiegand; Dyann F Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-31       Impact factor: 11.205

Review 4.  What can we learn from fitness landscapes?

Authors:  Daniel L Hartl
Journal:  Curr Opin Microbiol       Date:  2014-10-13       Impact factor: 7.934

5.  Intramolecular epistasis and the evolution of a new enzymatic function.

Authors:  Sajid Noor; Matthew C Taylor; Robyn J Russell; Lars S Jermiin; Colin J Jackson; John G Oakeshott; Colin Scott
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

6.  Nutrient Limitation Magnifies Fitness Costs of Antimalarial Drug Resistance Mutations.

Authors:  Shalini Nair; Xue Li; Grace A Arya; Marina McDew-White; Marco Ferrari; Tim Anderson
Journal:  Antimicrob Agents Chemother       Date:  2022-04-25       Impact factor: 5.938

7.  Modeling the evolution of drug resistance in malaria.

Authors:  David Hecht; Gary B Fogel
Journal:  J Comput Aided Mol Des       Date:  2012-11-21       Impact factor: 3.686

8.  Genetic diversity of Plasmodium falciparum and distribution of drug resistance haplotypes in Yemen.

Authors:  Salama Al-Hamidhi; Mohammed A K Mahdy; Zainab Al-Hashami; Hissa Al-Farsi; Abdulsalam M Al-mekhlafi; Mohamed A Idris; Albano Beja-Pereira; Hamza A Babiker
Journal:  Malar J       Date:  2013-07-15       Impact factor: 2.979

9.  In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.

Authors:  Leila S Ross; Francisco Javier Gamo; Maria José Lafuente-Monasterio; Onkar M P Singh; Paul Rowland; Roger C Wiegand; Dyann F Wirth
Journal:  J Biol Chem       Date:  2014-04-29       Impact factor: 5.157

10.  Replaying the tape of life: quantification of the predictability of evolution.

Authors:  Alexander E Lobkovsky; Eugene V Koonin
Journal:  Front Genet       Date:  2012-11-26       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.